Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the prospective Phase III KarMMa-3 study (NCT03651128) of idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T-cell therapy, for patients with relapsed/refractory (R/R) multiple myeloma. Patients with 2-4 prior lines of therapy will be randomized 2:1 to ide-cel or a standard regimen chosen based on the patient’s most recent line of therapy. The study will evaluate the safety and efficacy of ide-cel, with the hope to move CAR T-cells to an earlier line of treatment. Progression-free survival will be the primary endpoint. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.